What’s the current market cap for Arcus Biosciences stock?

Arcus Biosciences (RCUS) has a market cap of $3.9bn as of June 27, 2026.

What is the P/E ratio for Arcus Biosciences stock?

The price to earnings (P/E) ratio for Arcus Biosciences (RCUS) stock is 0 as of June 27, 2026.

Does Arcus Biosciences stock pay dividends?

No, Arcus Biosciences (RCUS) stock does not pay dividends to its shareholders as of June 27, 2026.

When is the next Arcus Biosciences dividend payment date?

Arcus Biosciences (RCUS) stock does not pay dividends to its shareholders.

What is the beta indicator for Arcus Biosciences?

Arcus Biosciences (RCUS) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Arcus Biosciences stock | $RCUS Share Price

About Arcus Biosciences

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Ticker

$RCUS

Sector

Health

Primary listing

NYSE

Employees

601

Headquarters

Hayward, United States

Website

arcusbio.com

RCUS Metrics

BasicAdvanced

$3.9bn

-

-$3.23

0.84

-

What the Analysts think about RCUS

Analyst ratings (Buy, Hold, Sell) for Arcus Biosciences stock.

Bulls say / Bears say

Updated late-line clear cell renal cell carcinoma data from the Phase 1/1b ARC-20 study showed a median progression-free survival of 15.1 months and a 45.2% confirmed overall response rate for the 100 mg once-daily casdatifan cohort, underscoring its best-in-class potential. (Business Wire)

Arcus plans to initiate a registrational Phase 3 study of casdatifan in first-line metastatic clear cell renal cell carcinoma by the end of 2026, targeting a potential $5 billion peak sales opportunity and diversifying its late-stage oncology pipeline. (Business Wire)

Arcus expects to fund operations until at least the second half of 2028, supported by approximately $1 billion in cash and equivalents, providing ample runway to advance its pipeline across multiple Phase 3 and early-stage programs. (Reuters)

Arcus reported first-quarter 2026 revenue of $17 million, down from $28 million a year earlier, and a net loss of $128 million, reflecting ongoing high cash burn and limited near-term revenue generation. (SEC 8-K Filing via StockTitan)

Arcus discontinued its Phase 3 STAR-121 study and Phase 2 EDGE-Lung study of domvanalimab plus zimberelimab in first-line metastatic non-small cell lung cancer after a futility analysis showed no overall survival benefit, removing a key pipeline catalyst. (SEC 8-K Filing via StockTitan)

Full-year 2026 GAAP revenue guidance of $50 million to $65 million underscores reliance on collaboration payments rather than product sales, raising questions about the company’s path to sustainable revenue growth. (SEC 8-K Filing via StockTitan)

Data summarised monthly by Lightyear AI. Last updated on 17 Jun 2026.

RCUS Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

RCUS Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

RCUS News

AllArticlesVideos

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire·3 days ago

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire·3 weeks ago

Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Business Wire·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.